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Abstract 
 
Introduction: Gut microbiota-dependent trimethylamine-N-oxide (TMAO) correlates with 
arterial thrombotic events including myocardial infarction and stroke, and mortality. However, 
the association of TMAO with recurrent venous thromboembolism (VTE) and mortality 
remains unknown. 
 
Methods: TMAO plasma levels were assessed by high performance liquid chromatography 
in 859 patients aged ≥65 years with acute VTE and categorized into low (<2.28µmol/L), 
medium (2.28–6.57µmol/L), and high levels (>6.57µmol/L) based on the 25th and 75th 
percentile. Associations of TMAO with recurrent VTE, major or non-major bleeding, and 
mortality were investigated. 
 
Results: During a mean follow-up of 28 months, 106 patients developed recurrent VTE, 259 
had major or non-major bleeding events, and 179 patients died. The risk of recurrent VTE did 
not differ significantly between patients with low, medium (adjusted subhazard ratio [SHR], 
1.38; 95% confidence interval [CI], 0.81 to 2.36; p=0.232) and high TMAO levels (SHR, 1.44; 
95% CI, 0.80 to 2.58, p=0.221). Compared with low TMAO levels, the adjusted hazard ratio 
[HR] for mortality was 0.68 (95% CI, 0.47 to 0.98, p=0.039) in patients with medium TMAO 
levels and 1.02 (95% CI, 0.68 to 1.52, p=0.922) in patients with high TMAO levels. Fractional 
polynomial Cox-regression confirmed a U-shaped association (adjusted p=0.045), with the 
lowest mortality risk in patients with TMAO around 4 µmol/L. TMAO was not associated with 
major or non-major bleeding. 
 
Conclusion: TMAO showed a U-shaped association with mortality in elderly patients with 
acute VTE and was not associated with recurrent VTE and major or non-major bleeding. 
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Abbreviations 
 
CI confidence interval 
HR hazard ratio 
IQ interquartile 
DVT deep vein thrombosis 
PE pulmonary embolism 
SHR subhazard ratio 
TMAO trimethylamine-N-oxide 
VTE venous thromboembolism 
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Introduction 
Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary 
embolism (PE); its incidence ranges between 1.4 to 2.2 per 1,000 person-years and 
increases exponentially with age. [1] Anticoagulation is considered standard therapy to 
reduce recurrent VTE; however, a residual thrombotic risk remains and importantly, bleeding 
risk increases substantially. [2] In the absence of long-term anticoagulation, up to 30% of 
patients suffer recurrent VTE in 10 years. [1] Due to the high incidence of recurrent VTE and 
post-thrombotic complications, [1] substantial VTE-related healthcare costs [3] and bleeding 
complications, [2] further strategies are needed to reduce the burden of VTE. 
Trimethylamine-N-oxide (TMAO), a gut microbiota-dependent metabolite of dietary 
phosphatidylcholine [4] and L-carnitine, [5] has been recently shown to increase the risk of 
arterial thrombotic events, such as myocardial infarction and stroke and consequently, 
overall mortality. [6, 7] Potential mechanisms underlying these observations include the 
propagation of atherosclerosis through activated monocytes/macrophages [4] as well as 
increased platelet activation and subsequent thrombotic arterial occlusion. [8] TMAO 
increases cholesterol uptake in macrophages leading to foam cell formation and thereby 
augments atherosclerotic lesion size converting arterial walls thrombogenic. [4] Further, it 
increases platelet aggregation and arterial thrombosis in rodents as well as human platelet 
adhesion and aggregation. [8] Both monocytes and platelets play a crucial role in the 
development of VTE. [9] During the initiation of venous thrombosis, monocytes and 
neutrophils are the dominant leukocytes adhering to venous vessel walls; likewise, platelets 
adhere to the endothelium and enhance leukocyte recruitment and neutrophil extracellular 
trap formation, [9] which is considered a crucial scaffold for venous thrombogenesis and in 
return activates platelet aggregation. [10-12] In line with this, platelet inhibition next to 
anticoagulation is recommended to prevent recurrent VTE. [2] 
To date, the role of TMAO in venous thrombosis remains unknown. We therefore examined 
the association of TMAO plasma levels with recurrent VTE, major or non-major bleeding, and 
mortality in a prospective multicenter cohort study of 859 elderly patients with acute VTE.  
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Methods 
Study population 
The current study is a sub-study of the Swiss Cohort of Elderly Patients with Venous 
Thromboembolism (SWITCO65+; ClinicalTrials.gov Identifier: NCT00973596), a prospective 
multicenter cohort study of elderly patients with acute VTE. [13] Patients were recruited from 
September 2009 to March 2012 (n=1003). Inclusion criteria were age above 65 years and 
symptomatic, objectively confirmed VTE (proximal and/or distal DVT and/or PE). [13] 
Symptomatic, objectively confirmed DVT was defined as proximal and/or distal DVT detected 
by an objective imaging exam (ultrasonography, spiral computed tomography or magnetic 
resonance imaging venography) in a patient with symptoms. [13] Symptomatic, objectively 
confirmed PE was defined as a PE detected by spiral computed tomography, a high-
probability ventilation-perfusion scintigraphy, pulmonary angiography or in the presence of 
objectively confirmed, symptomatic or asymptomatic proximal DVT in a patient with 
symptoms. [13] Exclusion criteria were inability to provide informed consent, conditions 
incompatible with follow-up, language barriers, thrombosis at a different site than lower limb, 
catheter-related thrombosis, or previous enrolment in the cohort. [13] After exclusion of 860 
patients (no consent, n = 398; inability to provide consent, n = 285; follow-up not possible, n 
= 192; other site than lower limb, n = 21; catheter-related thrombosis, n = 7; language 
barriers, n = 51; multiple reasons for exclusion may apply), 1003 patients were enrolled and 
144 patients were excluded from the current analysis (patients denying use of data, n = 8;, 
no biobank samples, n = 129; no TMAO measurement, n = 7); finally, TMAO was analyzed in 
859 patients. The study received ethical approval from every participated center and eligible 
patients provided informed consent. 
 
Baseline data collection and follow-up  
At baseline, demographic information, comorbidities, laboratory findings, VTE-related 
treatment before and after the event, and concomitant antiplatelet therapy were collected 
using standardized data collection forms. Follow-up contact included one telephone interview 
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and two face-to-face evaluations during the first year followed by semi-annual contacts and 
periodic reviews of the patient’s hospital chart. Patients were followed-up for 28 months on 
average. 
 
Blood sampling and determination of TMAO 
At baseline, heparin-anticoagulated blood was drawn after minimal venostasis; aliquots of 
samples were cryovialed in 3 ml polypropylene tubes and temporarily stored at -80°C before 
they were transported to and stored at the SWITCO65+ biobank at the Central Laboratory of 
Hematology of Lausanne University hospital, Switzerland. 
For the determination of TMAO, plasma samples were shipped to the Institute of Clinical 
Chemistry, University Hospital Zurich (Zurich, Switzerland). Levels of TMAO were quantified 
by liquid chromatography-mass spectrometry, similar as previously described. [14] Briefly, 
400 μL of an internal standard mixture containing TMAO-d9, at 1 μmol/L was added, 
vortexed and centrifuged (11’700 g, 10 min, 4 °C) and supernatant was analyzed. Separation 
was achieved on an Accucore HILIC column (50 x 2.1 mm, 2.6 μm particle size, Thermo 
Fisher Scientific, Reinach, Switzerland) under acidic conditions. As mass spectrometer, a 
QTrap 6500 hybrid instrument (Sciex) was used, that acquired chromatograms in positive 
electrospray ionization multi-reaction monitoring mode. The following transitions were used: 
76.1  59.1 (quantifier), 76.1  42.1 (qualifier 1), 76.1  56.2 (qualifier 2) for TMAO and 
85.1  68.1 for TMAO-d9. The modified method was validated and showed a good 
comparability to the original method described in [14]. All researchers involved in TMAO 
determination were blinded to patient characteristics and outcomes. 
 
End points 
The endpoints of the current study were recurrent VTE, major or non-major bleeding, and 
mortality. Recurrent VTE was defined as new fatal or new non-fatal PE, or new DVT 
(proximal and/or distal). [13] Diagnosis of recurrent DVT was performed by abnormal results 
on ultrasonography; recurrent PE was diagnosed by computed tomography, angiography, or 
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ventilation-perfusion lung scan; a new proximal DVT, associated with new PE symptom(s) 
was also considered as recurrent PE. [13] Major bleeding was defined as a fatal bleeding, 
symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, 
intraarticular, pericardial, or intramuscular with compartment syndrome), a reduction of 
hemoglobin ≥ 20 g/L or transfusion ≥ 2 units of packed red blood cells. [13] Non-major 
bleeding was defined as bleedings that did not fulfill the criteria for major bleeding but 
required medical attention. [13] 
 
Statistical analysis 
TMAO plasma levels were categorized into low, medium, and high levels based on the 25th 
and 75th percentile (low, <2.28 µmol/L; medium, 2.28 – 6.57 µmol/L; high, >6.57  µmol/L). We 
compared baseline characteristics of patients with different levels of plasma concentration of 
TMAO using the chi-squared test and the non-parametric Kruskal-Wallis test as appropriate. 
We estimated the cumulative incidence of a first VTE recurrence, a first major or non-major 
bleeding, and death during the first three years using the Kaplan-Meier method and 
compared survivor functions between groups by the log-rank test. Associations between 
plasma concentration of TMAO levels and the time to a first VTE recurrence and a first major 
or non-major bleeding were assessed by competing risk regression accounting for death as a 
competing event, according to the method of Fine and Gray [15]. The method yields 
subhazard ratios (SHR) with corresponding 95% confidence intervals (CIs) and p-values for 
the failure event of primary interest. For death, an ordinary Cox-regression was calculated. 
We adjusted the models for risk factors that had previously been shown to be associated 
with VTE recurrence, major or non-major bleeding, or mortality. VTE recurrence was 
adjusted for age, gender, overt PE, prior VTE, provoked index VTE and periods of 
anticoagulation. Mortality was adjusted for age, gender, overt PE, active cancer, 
immobilization during the last 3 months, chronic or acute heart failure, chronic lung disease 
and periods of anticoagulation. Bleeding was adjusted for age, active cancer, history of major 
bleeding, antiplatelet therapy, overt PE, and periods of anticoagulation. We verified 
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proportional-hazards assumptions using Schoenfeld residuals and time interactions. There 
was no significant interaction between time and TMAO levels, i.e. the effect of TMAO on 
outcomes did not change over time. Because a fractional polynomial Cox-regression 
suggested a U-shaped relationship between TMAO and death, we further investigated a 
quadratic relationship between log-transformed TMAO and death using a Cox model with a 
linear and quadratic term. Number of events and incidence rates per 100 person-years were 
displayed at 36 months for the total cohort and different TMAO levels. All analyses were 
done using Stata 14 (Stata Corporation, College Station, Texas). STROBE guidelines have 
been the basis for reporting our results. [16]  
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Results 
 
Study population 
The mean age was 75 years, and 45 % patients were female. The mean TMAO level was 
6.51 µmol/L. Patients’ baseline characteristics were largely comparable across TMAO 
categories. However, patients with high TMAO levels were slightly older, had less provoked 
index VTEs (defined as presence of ≥1 of the following factors: major surgery, oestrogen 
therapy, or immobilization during the last 3 months), had reduced glomerular filtration rates 
and were more likely to be hypertensive (Table 1). Mean follow-up was 28 months. 
 
Recurrent VTE 
During follow-up, 106 patients developed recurrent VTE. Patients with medium and high 
levels of TMAO were more likely to develop recurrent VTE after 3 years (low, 11.0 %; 
medium, 15.8 %; high, 16.1 %; p = 0.393) (Figure 1). After adjustment, medium TMAO levels 
were associated with a 38 % (adjusted SHR, 1.38; 95% CI, 0.81 to 2.36; p = 0.232) and high 
levels with a 44 % (adjusted SHR, 1.44; 95% CI, 0.80 to 2.58; p = 0.221) higher risk of 
developing recurrent VTE compared to low levels of TMAO; however, these observations did 
not reach statistical significance (Table 2). 
 
Mortality 
Death occurred in 179 patients during follow-up. The cumulative incidence of mortality 
differed significantly between TMAO levels (low, 22.5 %; medium, 17.4 %; high, 27.7 %; p = 
0.030) (Figure 2). After adjustment, the risk of mortality was significantly lower in patients 
with medium, as compared to patients with low levels of TMAO (adjusted hazard ratio [HR], 
0.68; 95% CI, 0.47 to 0.98; p = 0.039) (Table 2). On the other hand, patients with high TMAO 
levels had a comparable risk to patients with low TMAO levels for dying (adjusted HR, 1.02; 
95% CI, 0.68 to 1.52; p = 0.922) (Table 2) suggesting a U-shaped relationship between 
TMAO and mortality, which was confirmed in a fractional polynomial Cox-regression (Figure 
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3). In a model with a linear and quadratic term, we found a significant quadratic relationship 
between log-transformed TMAO and death (adjusted joint p = 0.045) (Table 3). The lowest 
number of events was observed in patients with TMAO around 4 µmol/L (Figure 3). At 3 
years, a total of 179 deaths were observed: 60 deaths (33.5 %) were attributable to cancer, 
33 (18.4 %) to PE (7 [3.9 %] PE related, 26 [14.5 %] possibly PE related), 16 (8.9 %) to 
sepsis, 14 (7.8%) to infection, 12 (6.7%) to left ventricular failure, 11 (6.2 %) to bleeding, 6 
(3.4 %) to pulmonary causes other than PE, 3 (1.7 %) to acute coronary syndrome, 2 (1.1 %) 
to stroke, 1 (0.6 %) to suicide, 5 (2.8 %) to others, and 16 (8.9 %) to unknown causes.  
 
Major or non-major bleeding 
The endpoint major or non-major bleeding occurred in 259 patients during follow-up. The 
cumulative incidence of major or non-major bleeding was comparable among different levels 
of TMAO (low, 36.0 %; medium, 33.5 %; high, 36.3 %, p = 0.817) (Figure 4). Likewise, after 
adjustment, the risk of major or non-major bleeding in patients with medium (adjusted SHR, 
0.96; 95% CI, 0.72 to 1.28; p = 0.775) and high TMAO levels (adjusted SHR, 0.94; 95% CI, 
0.67 to 1.32; p = 0.732) were comparable to low levels of TMAO (Table 2). 
 
Subgroup analysis for mortality 
In general, patients with PE are at higher risk of death, compared to patients with DVT. [1] In 
order to investigate whether the observed U-shaped association of TMAO and mortality was 
different in patients with PE compared to patients with DVT only, we performed a subgroup 
analysis. In our study, we found a comparable mortality between the two groups 
(Supplemental Table 1). The U-shaped association (i.e. lower risk in patients with medium as 
compared to low and high TMAO levels) was more pronounced in patients with PE than in 
patients with DVT only. However, a test for interaction between VTE type (PE versus DVT 
only) and TMAO levels was not significant. 
We also performed a subgroup analysis in patients with and without cancer, because cancer 
was the major contributor to mortality in the current study. The U-shaped association was 
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more pronounced in patients with cancer. However, a test for interaction between cancer and 
TMAO levels was not significant. Unfortunately, we cannot draw strong conclusions from 
these subgroup analyses, because 95% confidence intervals were rather wide and the power 
to detect differences between groups rather small. 
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Discussion 
In the current prospective multicenter cohort study we examined the association of gut 
microbiota-dependent TMAO with recurrent VTE, major or non-major bleeding, and mortality 
in patients at 65 years of age or above with acute VTE. We found that patients with medium 
and high TMAO levels had a 38 % and 44 % higher risk of developing recurrent VTE, 
respectively, compared with low levels of TMAO; however, these findings did not reach 
statistical significance. Interestingly, the risk of death was only reduced in patients with 
medium, but not in patients with high TMAO levels, as compared with low TMAO levels and 
we found a significant U-shaped association between log-transformed TMAO and mortality. 
More precisely, patients with TMAO plasma levels around 4 µmol/L had the lowest risk of 
death. Lastly, TMAO levels were not associated with major or non-major bleeding. 
Previous studies have investigated the associations between TMAO plasma levels and 
arterial thrombotic events including myocardial infarction and stroke as well as mortality in 
patients with previous myocardial infarction or in patients at high risk of cardiovascular 
events. [4, 6, 7, 14, 17, 18] Most [4, 6, 7], but not all of them [14, 17, 18] found high TMAO 
levels to be associated with an increased risk of atherothrombotic diseases. Potential 
pathophysiological mechanisms include the propagation of atherosclerosis by increased 
activation of monocytes/macrophages [4] and augmented arterial thrombosis mediated by 
increased platelet activation and aggregation through TMAO. [8] Although both monocytes 
and platelets are crucial for VTE development [9], we did not find a significant association 
between TMAO and recurrent VTE. In this study, median TMAO levels in the medium and 
high groups were 3.9 µmol/L and 10.6 µmol/L, respectively. Previous experimental studies 
showed that 10 to 31 µmol/L of TMAO were required in order to affect human platelet 
aggregation ex vivo and that arterial thrombosis was increased in mice with TMAO plasma 
levels of 100 µmol/L; [8] further, monocyte/macrophage activation and atherosclerosis was 
augmented in mice with TMAO plasma levels between 20 and 70 µmol/L. [4] Thus, one 
explanation for the missing association between TMAO and recurrent VTE might be that 
TMAO in the current study was slightly too low to affect venous thrombogenesis. In addition, 
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the studied population is of advanced age, which per se is associated with elevated levels of 
coagulation factors and inflammatory mediators; [19] in addition, VTE itself triggers 
inflammation and coagulation [20] and these mechanisms may have played a more relevant 
role for the development of VTE than the effects of TMAO on monocytes and platelets. 
The observation of a U-shaped association between log-transformed TMAO and mortality is 
novel. In contrast to our findings, previous longitudinal studies in patients with acute coronary 
syndrome, stable coronary heart disease, acute heart failure, chronic kidney disease or 
diabetes have reported linear associations between TMAO and mortality. [6, 7, 21-23] In 
addition, a recent meta-analysis in patients with coronary artery disease and patients at risk 
of cardio- and cerebrovascular disease also showed a positive direct and non-linear 
association of TMAO with mortality. [24] In this study we found that at baseline, patients with 
high TMAO levels were slightly older, had lower glomerular filtration rates and were more 
likely to be hypertensive. Mortality was corrected for age and the main causes of death were 
attributable to cancer and pulmonary embolism, which are not affected by hypertension and 
kidney function. TMAO is a gut microbiota-dependent metabolite and antibiotic treatment 
decreases TMAO levels substantially. [4, 6] Therefore, concomitant infectious diseases and 
the use of antibiotic therapy could explain the higher incidence of death in patients with low 
TMAO. Plasma levels of TMAO depend on the intake of fish as well as phosphatidylcholine 
and L-carnitine present in dairy products, eggs and red meat; therefore, malnutrition may be 
associated with both decreased TMAO levels and increased risk of mortality. [25] Body mass 
indices were comparable between the groups, which excludes underweight in patients with 
low TMAO; however, a normal body mass index does not exclude malnutrition in elderly 
patients. [26] 
Interestingly, TMAO levels in the present study were slightly higher than in previous Central 
European populations [14, 27-29] possibly due the advanced age of the current population 
and/or the high prevalence of comorbidities such as chronic kidney disease, glucose 
intolerance, and inflammation, conditions that have previously been shown to be associated 
with higher plasma levels of TMAO. [14, 29]  
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Strengths of our study include the large sample size. Further, TMAO measurements were 
performed in a standardized and reproducible manner. [14] The current study has several 
limitations. First, patients were recruited in Switzerland and were 65 years or above; thus, the 
findings are not applicable to the general population. Further, the high but non-significant 
SHR and the rather wide 95% confidence interval for recurrent VTE (1.48 (95% CI 0.88 to 
2.49) and 1.56 (95% CI 0.87 to 2.77) for medium and high TMAO levels, respectively) 
indicates a limited power to detect significant differences. The study is observational and only 
detects associations but not causality. Next, despite extensive adjustment, we cannot entirely 
exclude the possibility that the observed associations may be due to residual confounding or 
chance. Lastly, TMAO exhibits relevant intra-individual variation of roughly 45 % over a 1-
year period [28] and single measurements may not be representative for long-term follow-up. 
The association of TMAO with venous thrombosis remained unknown so far. In the current 
study we found a trend for an increased risk of recurrent VTE in the elderly, which, however, 
was not statistically significant. Whether a larger sample size may had reached significant 
results remains to be determined. Further, the association of TMAO with recurrent VTE in 
younger patients or in patients with primary rather than recurrent VTE should be investigated 
in future studies. A U-shaped relationship of TMAO with mortality has not been reported 
earlier and may be specific to patients with VTE or to an elderly population due to 
comorbidities and/or nutritional habits. Whether pharmacological changes of TMAO affect 
recurrent VTE, bleeding or mortality remains to be determined in randomized controlled 
intervention trials. 
In conclusion, TMAO showed a significant U-shaped association with mortality in elderly 
patients with acute VTE. The lowest number of events was observed in patients with TMAO 
around 4 µmol/L. Contrary to arterial thrombosis, TMAO was not associated with recurrent 
VTE and TMAO did not correlate with major or non-major bleeding. 
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Legends to Figures and Tables 
 
Figure 1. Kaplan–Meier estimates of recurrent VTE by TMAO levels. After 3 years, the 
cumulative incidence of recurrent VTE was higher in patients with medium and high levels of 
TMAO than in patients with low levels, but differences were not statistically significant (low, 
11.0 %; medium, 15.8 %; high, 16.1 %; p = 0.393). 
 
Figure 2. Kaplan–Meier estimates to mortality by TMAO levels. After 3 years, the 
cumulative incidence of mortality varied significantly between patients with different levels of 
TMAO (low, 22.5 %; medium, 17.4 %; high, 27.7 %; p = 0.030). 
 
Figure 3. Relative hazards for mortality according to TMAO levels. Fractional polynomial 
Cox-regression showed a U-shaped association between log-transformed TMAO and death. 
The lowest risk of death was observed in patients presenting with TMAO around 4 µmol/L. 
 
Figure 4. Kaplan–Meier estimates of major or non-major bleeding by TMAO levels. 
After 3 years, the cumulative incidence of major or non-major bleeding was comparable 
between different levels of TMAO (low, 36.0 %; medium, 33.5 %; high, 36.3 %, p = 0.817). 
 
Table 1. Baseline characteristics by TMAO levels. 
Values were missing in body mass index (1 %), systolic blood pressure (2 %), GFR (8 %), 
anaemia (6 %), and platelet count (6 %). Provoked VTE was defined as presence of ≥1 of 
the following factors: major surgery, oestrogen therapy, or immobilization during the last 3 
months; polypharmacy was defined as prescription of more than four different drugs. GFR = 
glomerular filtration rate, IQ = interquartile, TMAO = trimethylamine-N-oxide; PE = pulmonary 
embolism, TIA = transient ischemic attack, VTE = venous thromboembolism. 
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Table 2. Association of TMAO with clinical end points after entire follow-up. 
VTE recurrence was adjusted for age, gender, overt PE, prior VTE, provoked index VTE and 
periods of anticoagulation. Mortality was adjusted for age, gender, overt PE, active cancer, 
immobilization during the last 3 months, chronic or acute heart failure, chronic lung disease 
and periods of anticoagulation. Bleeding was adjusted age, active cancer, history of major 
bleeding, antiplatelet therapy, overt PE, and periods of anticoagulation. HR = hazard ratio, IR 
= incidence rate (per 100 patient-years), PE = pulmonary embolism, SHR = subhazard ratio, 
TMAO = Trimethylamine-N-oxide, VTE = venous thromboembolism. 
 
Table 3. Association of TMAO with Mortality – quadratic modeling. 
The adjusted joint p-value for both the linear and quadratic term was 0.045. Mortality was 
adjusted for age, gender, overt PE, active cancer, immobilization during the last 3 months, 
chronic or acute heart failure, chronic lung disease and periods of anticoagulation. HR = 
hazard ratio, IR = incidence rate, PE = pulmonary embolism, TMAO = Trimethylamine-N-
oxide, VTE = venous thromboembolism. 
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Tables 
Table 1. Baseline characteristics by TMAO levels.  
 All Low 
<2.28 µmol/L 
Medium 
2.28-6.57 µmol/L 
High 
>6.57 µmol/L 
p-
value 
  n (%) or median 
(IQ-range) 
n (%) or median 
(IQ-range) 
n (%) or median 
(IQ-range) 
n (%) or median 
(IQ-range) 
 
Total N 859 214 430 215  
Age 75.0 
(69.0; 81.0) 
74.0 
(69.0; 80.0) 
74.0 
(69.0; 80.0) 
76.0 
(71.0; 83.0) 
0.005 
Female 386 (45%) 104 (49%) 185 (43%) 97 (45%) 0.407 
BMI 26.6  
(24.1; 29.8) 
26.2 
(23.8; 29.4) 
26.7 
(24.2; 29.8) 
27.0 
(23.8; 30.2) 
0.222 
Overt PE 599 (70%) 164 (77%) 293 (68%) 142 (66%) 0.035 
Prior VTE 251 (29%) 54 (25%) 134 (31%) 63 (29%) 0.297 
Major surgery during the 
last 3 months 
130 (15%) 40 (19%) 67 (16%) 23 (11%) 0.065 
Current oestrogen therapy 
during the last 3 months 
27 (3%) 6 (3%) 14 (3%) 7 (3%) 0.951 
Immobilization during the 
last 3 months 
185 (22%) 54 (25%) 95 (22%) 36 (17%) 0.094 
Provoked index VTE 252 (29%) 73 (34%) 132 (31%) 47 (22%) 0.014 
Active cancer 157 (18%) 43 (20%) 73 (17%) 41 (19%) 0.592 
History of major bleeding 89 (10%) 23 (11%) 38 (9%) 28 (13%) 0.257 
Arterial hypertension 549 (64%) 123 (57%) 271 (63%) 155 (72%) 0.006 
Systolic blood pressure 135.0 
(120.0; 150.0) 
130.0 
(119.5; 148.5) 
138.0 
(125.0; 150.0) 
134.0 
(120.5; 146.5) 
0.028 
Chronic/acute heart failure 102 (12%) 27 (13%) 47 (11%) 28 (13%) 0.687 
Diabetes 190 (22%) 43 (20%) 88 (20%) 59 (27%) 0.094  
HbA1c [%] 5.7 (5.4; 6.1) 5.7 (5.4; 6.1) 5.7 (5.4; 6.1) 5.8 (5.5; 6.2) 0.088 
Cerebrovascular disease 
(stroke, TIA) 
82 (10%) 16 (7%) 39 (9%) 27 (13%) 0.180 
Chronic renal disease 156 (18%) 24 (11%) 70 (16%) 62 (29%) <0.001 
GFR [mL/min/1.73m2] 58.1 
(47.4; 73.6) 
66.2 
(53.6; 82.2) 
58.5 
(49.3; 74.1) 
49.6 
(36.7; 62.0) 
<0.001 
Anaemia 333 (39%) 94 (44%) 156 (36%) 83 (39%) 0.378 
Platelet count <150 G/l 130 (15%) 25 (12%) 69 (16%) 36 (17%) 0.171 
Polypharmacy 439 (51%) 108 (50%) 214 (50%) 117 (54%) 0.525 
Anticoagulation prior to 
index VTE 
41 (5%) 13 (6%) 20 (5%) 8 (4%) 0.513 
Type of initial parenteral 
anticoagulation 
    0.094 
 LMWH 410 (48%) 97 (45%) 212 (49%) 101 (47%)  
 UFH 272 (32%) 79 (37%) 123 (29%) 70 (33%)  
 Fondaparinux 147 (17%) 27 (13%) 81 (19%) 39 (18%)  
 Danaparoid 1  (0%) 0  (0%) 0  (0%) 1  (0%)  
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 None 29  (3%) 11  (5%) 14  (3%) 4  (2%)  
Initial VKA therapy 746 (87%) 178 (83%) 380 (88%) 188 (87%) 0.177 
Antiplatelet therapy 275 (32%) 62 (29%) 138 (32%) 75 (35%) 0.422 
Aspirin 243 (28%) 57 (27%) 120 (28%) 66 (31%) 0.627 
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Table 2. Association of TMAO with clinical end points after entire follow-up. 
End point TMAO 
levels 
N° of 
patients 
N° events/ 
patient-
years 
IR (95% CI) Crude SHR or 
HR (95% CI) 
p-
value 
Adjusted SHR or 
HR (95%-CI) 
p-
value 
VTE 
recurrence 
All 859 106 / 1809.1 5.9 (4.8 to 7.1)     
Low 214 19 / 446.6 4.3 (2.7 to 6.7) 1 (reference)  1 (reference)  
Medium 430 57 / 924.3 6.2 (4.8 to 8.0) 1.48 (0.88 to 2.49) 0.142 1.38 (0.81 to 2.36) 0.232 
High 215 30 / 438.2 6.8 (4.8 to 9.8) 1.56 (0.87 to 2.77) 0.133 1.44 (0.80 to 2.58) 0.221 
Mortality All 859 179 / 1921.2 9.3 (8.0 to 10.8)     
Low 214 46 / 456.0 10.1 (7.6 to 13.5) 1 (reference)  1 (reference  
Medium 430 75 / 1003.4 7.5 (6.0 to 9.4) 0.75 (0.52 to 1.09) 0.130 0.68 (0.47 to 0.98) 0.039 
High 215 58 / 461.7 12.6 (9.7 to 16.2) 1.21 (0.82 to 1.78) 0.340 1.02 (0.68 to 1.52) 0.922 
Major or 
non-major 
bleeding 
All 859 259 / 1565.1 16.5 (14.7 to 18.7)     
Low 214 66 / 374.2 17.6 (13.9 to 22.4) 1 (reference)  1 (reference)  
Medium 430 126 / 799.2 15.8 (13.2 to 18.8) 0.95 (0.71 to 1.28) 0.753 0.96 (0.72 to 1.28) 0.775 
High 215 67 / 391.7 17.1 (13.5 to 21.7) 1.01 (0.72 to 1.42) 0.933 0.94 (0.67 to 1.32) 0.732 
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Table 3. Association of TMAO with Mortality – quadratic modeling. 
End point TMAO levels Crude HR 
(95% CI) 
p-
value 
Adjusted HR 
(95%-CI) 
p-
value 
Mortality log (TMAO) 0.73 (0.53 to 1.00) 0.048 0.73 (0.53 to 0.98) 0.039 
log(TMAO)2 1.13 (1.04 to 1.23) 0.004 1.11 (1.02 to 1.21) 0.013 
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Figures 
 
Figure 1 
 
 
Figure 2 
 
  
Published in final edited form as: Thromb Res. 2019 Feb;174:40-47. doi: 10.1016/j.thromres.2018.12.011 
 28 
Figure 3 
 
 
Figure 4 
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Supplemental Table 
Supplemental Table 1. Subgroup analysis for mortality. 
Subgroup TMAO 
levels 
N° events/ 
N° patients 
Crude HR 
(95% CI) 
p-
value 
Adjusted HR 
(95%-CI) 
p-value 
Patients with 
overt PE 
All 121/599     
Low 37/164 1 (reference)  1 (reference)  
Medium 49/293 0.70 (0.46 to 1.07) 0.101 0.65 (0.42 to 0.99) 0.047 
High 35/142 1.04 (0.66 to 1.66) 0.854 0.94 (0.58 to 1.51) 0.788 
Patients with 
DVT only 
All 58/260     
Low 9/50 1 (reference)  1 (reference  
Medium 26/137 0.95 (0.44 to 2.02) 0.887 0.92 (0.41 to 2.04) 0.829 
High 23/73 1.74 (0.80 to 3.76) 0.160 1.53 (0.67 to 3.49) 0.308 
Patients 
without 
cancer 
All 96/702     
Low 22/171 1 (reference)  1 (reference  
Medium 41/357 0.86 (0.51 to 1.45) 0.573 0.99 (0.59 to 1.68) 0.979 
High 33/174 1.46 (0.85 to 2.50) 0.172 1.37 (0.79 to 2.36) 0.266 
Patients with 
cancer 
All 83/157     
Low 24/43 1 (reference)  1 (reference  
Medium 34/73 0.62 (0.37 to 1.05) 0.077 0.55 (0.32 to 0.95) 0.032 
High 25/41 0.89 (0.51 to 1.57) 0.694 0.71 (0.39 to 1.30) 0.267 
 
The adjusted HR in subgroup analysis for patients with overt PE and DVT only was corrected 
for age, gender, active cancer, immobilization during the last 3 months, chronic or acute 
heart failure, chronic lung disease and AC as time-varying covariate. The adjusted HR in 
subgroup analysis for patients with vs. without cancer was corrected for age, gender, overt 
PE, immobilization during the last 3 months, chronic or acute heart failure, chronic lung 
disease and AC as time-varying covariate. HR = hazard ratio, DVT = deep venous 
thrombosis, PE = pulmonary embolism, TMAO = Trimethylamine-N-oxide.  
 
